Confirmation of post offer intention statements

Investec

14/05/2026 07:00

RNS Number : 2209E

DBAY Advisors Limited

14 May 2026

 

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") WHICH, INTER ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF A PERIOD OF 12 MONTHS FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED INTENTIONS.

FOR IMMEDIATE RELEASE

14 May 2026

 

Aegros Bidco Limited

Rule 19.6(c) confirmation in respect of stated post-offer intentions for Alliance Pharma plc

Aegros Bidco Limited ("Bidco") announces that, further to the completion of the recommended acquisition of Alliance Pharma plc ("Alliance Pharma") pursuant to which Bidco (a newly incorporated company indirectly owned by funds and corporate vehicles managed and/or advised by  DBAY Advisors Limited, and Edmond de Rothschild Equity Strategies IV SLP) acquired the entire issued and to be issued share capital of Alliance Pharma by means of a court-approved scheme of arrangement which became effective on 14 May 2025, Bidco has duly confirmed in writing to the Takeover Panel in accordance with the requirements of Rule 19.6(c) of the Code that it has complied with the post-offer intention statements made pursuant to Rules 2.7(c)(viii) and 24.2 of the Code, as originally detailed in its announcement made under Rule 2.7 of the Code on 10 January 2025, and the scheme circular published on 31 January 2025.

 

Contacts:

Bidco/DBAY
+44 (0) 1624 602130
Samuel Tresidder
Michael Haxby
Investec Bank plc (Financial Adviser to Bidco and DBAY)
+44 (0) 20 7597 5197
Gary Clarence
Harry Hargreaves


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
OUPBUGDUSXBDGLX